Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Sep 10, 2026 to Nov 15, 2023
    • Eligibility criteria expanded, about 15 words
    • Site details revised
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 36
    • Site details revised
    v7
  3. 3 versions Re-verified since Sep 27, 2022, no change to tracked fieldsv4-v6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 10, 2021 to Sep 1, 2021
    • Site details revised
    v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.
Trial Details
NCT Number NCT05045027
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: United States Department of Defense
Conditions
(from sponsor)		 Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
Related terms Glioma
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov